Johor Bahru, October 2024 – A team of researchers from Universiti Teknologi Malaysia (UTM) has unveiled an innovative solution for the treatment of chronic wounds. The Protease Debridement Cream, formulated with a novel recombinant serine protease from Bacillus sp., promises a breakthrough in eschar debridement and the removal of bacterial biofilms, paving the way for faster wound healing and improved patient outcomes.
This cutting-edge cream offers dual-action effectiveness, breaking down dead tissue (eschar) within an hour while degrading harmful bacterial biofilms within 24 hours. The product has been engineered to act rapidly and non-invasively, addressing key challenges in wound care. According to the research team, the cream can achieve up to 50% eschar degradation and 73% biofilm removal within a day, all while preserving healthy tissue.
Dr. Wan Rosmiza Zana Wan Dagang, who leads the UTM research team, explains, “Our cream represents a significant advancement in wound care. By offering both eschar removal and biofilm degradation in a single application, we can provide faster, more efficient healing for chronic wound patients. This is especially important in resource-limited settings, where traditional debridement methods may not be accessible.”
The cream is available in two formulations: a lighter lotion containing liquid SPB for standard cases, and a heavier cream with freeze-dried SPB for more severe wounds. Its flexibility and efficiency make it ideal for use in various healthcare settings, including hospitals, pharmaceutical companies, home healthcare services, and even government health agencies.
This innovative solution is set to have a broad market impact, offering a cost-effective alternative to existing debridement methods, which are often invasive and time-consuming. “The potential market for this product is vast,” says Dr. Haryati Jamaluddin, one of the key researchers. “From health providers and hospitals to biotech firms and research institutions, this cream could revolutionize how we treat chronic wounds.”
The development team also includes Dr. Julia Yunus and Dr. Mohd Anuar Jonet, working collaboratively to bring this groundbreaking product to the global market. With its patent filed under IP/CR/02786 and patent number IP/PT/02510, the Protease Debridement Cream is ready to make waves in the medical field.
As UTM continues to push the boundaries of scientific innovation, this product offers a safer, more efficient solution for chronic wound care, poised to improve patient outcomes worldwide.
